Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for cerebral palsy: drug may tame involuntary movements

NCT ID NCT05206513

Symptom relief Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called valbenazine to see if it can reduce jerky, uncontrolled movements (chorea) in people with cerebral palsy. The trial included 86 children and adults whose medical condition was stable. Participants received either valbenazine or a placebo for 14 weeks, and researchers measured changes in movement severity using standard rating scales.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

86 people

The number who actually took part.

Started

Apr 2022

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Medically confirmed diagnosis of DCP (that is, a hyperkinetic movement disorder due to cerebral palsy \[CP\]) with choreiform movements. 2. Medical conditions are stable and expected to remain stable throughout the study. Key Exclusion Criteria: Participants will be excluded from the study if they meet any of the following criteria: 1. Are pregnant or breastfeeding. 2. Have a clinical diagnosis or history of dyskinesia due to condition other than CP. 3. Have inability to swallow soft foods, unless medications can be administered via gastrostomy/gastrojejunostomy tube. 4. Have any suicidal behavior or suicidal ideation in the year prior to screening or on Day 1. 5. Is a substance abuser of any compound. 6. Known history of long QT syndrome or cardiac tachyarrhythmia, or clinically significant electrocardiogram (ECG) abnormalities.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral palsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Athetosis cerebral palsy choreatic disease Dyskinesias Dystonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral palsy Dyskinesia

Contacts and locations

Locations

  • Neurocrine Clinical Site

    San Diego, California, 92123, United States

  • Neurocrine Clinical Site

    Aurora, Colorado, 80045, United States

  • Neurocrine Clinical Site

    Stamford, Connecticut, 06905, United States

  • Neurocrine Clinical Site

    Gulf Breeze, Florida, 32561, United States

  • Neurocrine Clinical Site

    Miami, Florida, 33155, United States

  • Neurocrine Clinical Site

    Orlando, Florida, 32806, United States

  • Neurocrine Clinical Site

    Chicago, Illinois, 60611, United States

  • Neurocrine Clinical Site

    Baltimore, Maryland, 21205, United States

  • Neurocrine Clinical Site

    Boston, Massachusetts, 02115, United States

  • Neurocrine Clinical Site

    Farmington Hills, Michigan, 48334, United States

  • Neurocrine Clinical Site

    Saint Paul, Minnesota, 55101, United States

  • Neurocrine Clinical Site

    New York, New York, 10003, United States

  • Neurocrine Clinical Site

    Cincinnati, Ohio, 45229, United States

  • Neurocrine Clinical Site

    Columbus, Ohio, 43205, United States

  • Neurocrine Clinical Site

    Oklahoma City, Oklahoma, 73120, United States

  • Neurocrine Clinical Site

    Portland, Oregon, 97239, United States

  • Neurocrine Clinical Site

    Dallas, Texas, 75390-8857, United States

  • Neurocrine Clinical Site

    Fort Worth, Texas, 76104, United States

  • Neurocrine Clinical Site

    Houston, Texas, 77030, United States

  • Neurocrine Clinical Site

    Buenos Aires, C1060AAF, Argentina

  • Neurocrine Clinical Site

    Buenos Aires, C1425EFD, Argentina

  • Neurocrine Clinical Site

    Brussels, 1200, Belgium

  • Neurocrine Clinical Site

    Brasília, 70684-831, Brazil

  • Neurocrine Clinical Site

    Curitiba, 80250-060, Brazil

  • Neurocrine Clinical Site

    Porto Alegre, 90035-001, Brazil

  • Neurocrine Clinical Site

    Porto Alegre, 90050-170, Brazil

  • Neurocrine Clinical Site

    Ẕerifin, 7030000, Israel

  • Neurocrine Clinical Site

    Calambrone, 56128, Italy

  • Neurocrine Clinical Site

    Milan, 3. 20162, Italy

  • Neurocrine Clinical Site

    Aguascalientes, Mexico

  • Neurocrine Clinical Site

    Gdansk, 80-389, Poland

  • Neurocrine Clinical Site

    Krakow, 30-539, Poland

  • Neurocrine Clinical Site

    Oświęcim, 32-600, Poland

  • Neurocrine Clinical Site

    Lisbon, 1169-045, Portugal

  • Neurocrine Clinical Site

    Lisbon, 1649-035, Portugal

  • Neurocrine Clinical Site

    Porto, 4050-651, Portugal

  • Neurocrine Clinical Site

    Barcelona, 08038, Spain

  • Neurocrine Clinical Site

    Madrid, 28006, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.